[go: up one dir, main page]

MX2018005215A - Derivados de n-[2-(1-bencilpiperidin-4-il)etil]-4-(pirazin-2-il)-p iperazin-1-carboxamida y compuestos relacionados como antagonistas del receptor muscarinico 4 (m4) para el tratamiento de enfermedades neurologicas. - Google Patents

Derivados de n-[2-(1-bencilpiperidin-4-il)etil]-4-(pirazin-2-il)-p iperazin-1-carboxamida y compuestos relacionados como antagonistas del receptor muscarinico 4 (m4) para el tratamiento de enfermedades neurologicas.

Info

Publication number
MX2018005215A
MX2018005215A MX2018005215A MX2018005215A MX2018005215A MX 2018005215 A MX2018005215 A MX 2018005215A MX 2018005215 A MX2018005215 A MX 2018005215A MX 2018005215 A MX2018005215 A MX 2018005215A MX 2018005215 A MX2018005215 A MX 2018005215A
Authority
MX
Mexico
Prior art keywords
disorders
disease
related compounds
neurological diseases
carboxamide
Prior art date
Application number
MX2018005215A
Other languages
English (en)
Other versions
MX386148B (es
Inventor
Harriott Nicole
PAGANO Nicholas
Original Assignee
Neurocrine Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurocrine Biosciences Inc filed Critical Neurocrine Biosciences Inc
Publication of MX2018005215A publication Critical patent/MX2018005215A/es
Publication of MX386148B publication Critical patent/MX386148B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Se proporcionan compuestos de moléculas pequeñas de la siguiente fórmula (I:) (ver Fórmula) o un estereoisómero, tautómero, solvato, éster, profármaco, o sal farmacéuticamente aceptable del mismo, donde A, B, C, L1, L2, R1, R2, R3, R4, R5, w, x, y y z son como se define este documento. También se proporcionan métodos para tratar enfermedades/trastornos antagonizando receptores muscarínicos, incluyendo específicamente antagonizar el receptor muscarínico 4 (M4).
MX2018005215A 2015-11-06 2016-11-04 Derivados de n-[2-(1-bencilpiperidin-4-il)etil]-4-(pirazin-2-il)-piperazin-1-carboxamida y compuestos relacionados como antagonistas del receptor muscarinico 4 (m4) para el tratamiento de enfermedades neurologicas. MX386148B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562252179P 2015-11-06 2015-11-06
US201662275708P 2016-01-06 2016-01-06
PCT/US2016/060659 WO2017079641A1 (en) 2015-11-06 2016-11-04 N-[2-(1 -benzylpiperidin-4-yl)ethyl]-4-(pyrazin-2-yl)-piperazine-1 -carboxamide derivatives and related compounds as muscarinic receptor 4 (m4) antagonists for treating neurological diseases

Publications (2)

Publication Number Publication Date
MX2018005215A true MX2018005215A (es) 2018-08-01
MX386148B MX386148B (es) 2025-03-18

Family

ID=57349137

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018005215A MX386148B (es) 2015-11-06 2016-11-04 Derivados de n-[2-(1-bencilpiperidin-4-il)etil]-4-(pirazin-2-il)-piperazin-1-carboxamida y compuestos relacionados como antagonistas del receptor muscarinico 4 (m4) para el tratamiento de enfermedades neurologicas.

Country Status (22)

Country Link
US (2) US11033539B2 (es)
EP (1) EP3371164B1 (es)
JP (2) JP6917989B2 (es)
KR (1) KR20180073685A (es)
CN (1) CN108349936B (es)
AU (1) AU2016348524B2 (es)
BR (1) BR112018008630A2 (es)
CA (1) CA3001873A1 (es)
CL (1) CL2018001217A1 (es)
CO (1) CO2018004800A2 (es)
ES (1) ES2915266T3 (es)
HK (1) HK1253029A1 (es)
IL (1) IL258862B (es)
MA (1) MA43168A (es)
MX (1) MX386148B (es)
MY (1) MY194461A (es)
PE (1) PE20181010A1 (es)
PH (1) PH12018500940A1 (es)
SA (1) SA518391518B1 (es)
SG (1) SG11201803757UA (es)
TN (1) TN2018000130A1 (es)
WO (1) WO2017079641A1 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016348493B2 (en) 2015-11-06 2021-02-25 F. Hoffmann-La Roche Ag Indolin-2-one derivatives
PE20181010A1 (es) * 2015-11-06 2018-06-26 Neurocrine Biosciences Inc Derivados de n-[2-(1-benzilpiperidin-4-il)etil]-4-(pirazin-2-il)-piperazina-1-carboxamida y compuestos relacionados como antagonistas del receptor muscarinico 4 (m4) para tratar trastornos neurologicos
AU2018313802A1 (en) 2017-08-08 2020-02-20 Vanderbilt University Antagonists of the muscarinic acetylcholine receptor M4
WO2019079410A1 (en) 2017-10-17 2019-04-25 Vanderbilt University ANTAGONISTS OF THE MUSCARINIC RECEPTOR OF ACETYLCHOLINE M4
KR20250037575A (ko) 2017-10-20 2025-03-17 반더빌트유니버시티 무스카린성 아세틸콜린 수용체 m4의 길항제
AU2018360581A1 (en) 2017-10-31 2020-06-11 Vanderbilt University Antagonists of the muscarinic acetylcholine receptor M4
US11325896B2 (en) 2017-12-20 2022-05-10 Vanderbilt University Antagonists of the muscarinic acetylcholine receptor M4
AU2019216492A1 (en) * 2018-02-02 2020-08-20 Vanderbilt University Antagonists of the muscarinic acetylcholine receptor M4
CR20200464A (es) 2018-03-08 2021-04-14 Incyte Corp Compuestos diólicos de aminopirazina como inhibidores de pi3k-y
US11046658B2 (en) 2018-07-02 2021-06-29 Incyte Corporation Aminopyrazine derivatives as PI3K-γ inhibitors
WO2020048828A1 (en) 2018-09-03 2020-03-12 Bayer Pharma Aktiengesellschaft 5-heteroaryl-3,9-diazaspiro[5.5]undecane compounds
WO2020048827A1 (en) 2018-09-03 2020-03-12 Bayer Aktiengesellschaft 1, 3, 9-triazaspiro[5.5] undecan-2-one compounds
WO2020048826A1 (en) 2018-09-03 2020-03-12 Bayer Aktiengesellschaft 5-substituted 1-oxa-3,9-diazaspiro[5.5]undecan-2-one compounds
CN112638381B (zh) * 2018-09-04 2024-08-30 康蒂内乌姆医疗公司 毒蕈碱性乙酰胆碱m1受体拮抗剂
AU2020297422B2 (en) * 2019-06-17 2024-03-21 Deciphera Pharmaceuticals, Llc Aminopyrimidine amide autophagy inhibitors and methods of use thereof
CA3150906A1 (en) * 2019-09-17 2021-03-25 Renato T. Skerlj Substituted, saturated and unsaturated n-heterocyclic carboxamides and related compounds for their use in the treatment of medical disorders
US11752149B2 (en) 2019-12-02 2023-09-12 Pipeline Therapeutics, Inc. Muscarinic acetylcholine M1 receptor antagonists
EP4069367B1 (en) 2019-12-06 2024-05-15 Neurocrine Biosciences, Inc. Muscarinic receptor 4 antagonists and methods of use
CN111072551A (zh) * 2019-12-30 2020-04-28 上海睿瓦科技有限公司 催化氢化一步法制取哌啶胺的方法
EP4100410A1 (en) * 2020-02-05 2022-12-14 Neurocrine Biosciences, Inc. Muscarinic receptor 4 antagonists and methods of use
WO2022156708A1 (en) * 2021-01-20 2022-07-28 Jacobio Pharmaceuticals Co., Ltd. Parp7 enzyme inhibitor
CA3220429A1 (en) * 2021-06-11 2022-12-15 Neuronascent, Inc. Methods and compositions for lipid formulation of lipophilic small molecule therapies of the heterocyclic type
KR20240042472A (ko) * 2021-07-30 2024-04-02 뉴로크린 바이오사이언시즈 인코퍼레이티드 무스카린성 수용체 4 길항제 및 사용 방법
JP2025539787A (ja) * 2022-11-16 2025-12-09 ヴァーンウィ セラピューティクス，インコーポレイテッド Ｔｙｋ２阻害剤

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2126976A1 (en) * 1991-12-31 1993-07-08 Hisashi Takasugi Oxadiazole derivatives having acetylcholinesterase-inhibitory and muscarinic agonist activity
GB9313201D0 (en) * 1993-06-25 1993-08-11 Fujisawa Pharmaceutical Co New heterocyclic compounds
US5700801A (en) 1994-12-23 1997-12-23 Karl Thomae, Gmbh Piperazine derivatives, pharmaceutical compositions containing these compounds, their use and processes for preparing them
CN1279668A (zh) * 1997-11-18 2001-01-10 帝人株式会社 环胺衍生物及其作为药物的用途
EP1179341B1 (en) * 1999-05-18 2005-11-09 Teijin Limited Remedies or preventives for diseases in association with chemokines
EP1214299B1 (en) * 1999-09-22 2004-04-14 Schering Corporation Muscarinic antagonists
ATE346042T1 (de) * 1999-12-08 2006-12-15 Teijin Ltd Zyklische aminverbindungen als ccr5-rezeptor antagonisten
US6410566B1 (en) * 2000-05-16 2002-06-25 Teijin Limited Cyclic amine derivatives and their use as drugs
JPWO2003062234A1 (ja) 2002-01-23 2005-05-19 山之内製薬株式会社 キノキサリン化合物
US8673924B2 (en) * 2002-09-04 2014-03-18 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors
CN1744899A (zh) * 2002-12-13 2006-03-08 史密丝克莱恩比彻姆公司 作为ccr5拮抗剂的哌啶衍生物
TW200536830A (en) 2004-02-06 2005-11-16 Chugai Pharmaceutical Co Ltd 1-(2H)-isoquinolone derivative
EP1904446A2 (en) * 2005-07-11 2008-04-02 Ranbaxy Laboratories Limited Azabicyclo derivatives as muscarinic receptor antagonists
MX2008008337A (es) 2005-12-21 2008-09-03 Schering Corp Fenoxipiperidinas y sus analogos utiles como antagonistas de histamina h3.
WO2007130383A2 (en) 2006-04-28 2007-11-15 Northwestern University Compositions and treatments using pyridazine compounds and secretases
EP1997805A1 (en) * 2007-06-01 2008-12-03 Commissariat à l'Energie Atomique Compounds with antiparasitic activity, applications thereof to the treatment of infectious diseases caused by apicomplexans
JP2013028538A (ja) * 2009-11-13 2013-02-07 Dainippon Sumitomo Pharma Co Ltd 新規アミド誘導体
EP2788328B1 (en) 2011-11-25 2018-01-31 Nerviano Medical Sciences S.r.l. 3-phenyl-isoquinolin-1(2h)-one derivatives as parp-1 inhibitors
WO2014074517A1 (en) * 2012-11-08 2014-05-15 Emory University Cellular compositions used to restore stem cell or progenitor cell function and methods related thereto
CN104812387A (zh) 2012-11-20 2015-07-29 霍夫曼-拉罗奇有限公司 取代的1,6-萘啶
CN105102442B (zh) 2013-03-18 2018-11-09 基因科学医药公司 作为抗癌药的喹啉衍生物
JP6272832B2 (ja) 2013-04-04 2018-01-31 武田薬品工業株式会社 複素環化合物
AU2014320149A1 (en) * 2013-09-11 2016-04-07 Institute Of Cancer Research: Royal Cancer Hospital (The) 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use
SG10201914111XA (en) 2014-03-20 2020-03-30 Samumed Llc 5-substituted indazole-3-carboxamides and preparation and use thereof
PE20181010A1 (es) * 2015-11-06 2018-06-26 Neurocrine Biosciences Inc Derivados de n-[2-(1-benzilpiperidin-4-il)etil]-4-(pirazin-2-il)-piperazina-1-carboxamida y compuestos relacionados como antagonistas del receptor muscarinico 4 (m4) para tratar trastornos neurologicos

Also Published As

Publication number Publication date
CN108349936A (zh) 2018-07-31
US20210338653A1 (en) 2021-11-04
CN108349936B (zh) 2021-10-01
US11033539B2 (en) 2021-06-15
IL258862A (en) 2018-06-28
MA43168A (fr) 2018-09-12
SG11201803757UA (en) 2018-06-28
BR112018008630A2 (pt) 2018-10-30
JP6917989B2 (ja) 2021-08-11
PH12018500940A1 (en) 2018-12-17
EP3371164A1 (en) 2018-09-12
KR20180073685A (ko) 2018-07-02
CA3001873A1 (en) 2017-05-11
MX386148B (es) 2025-03-18
US20180325887A1 (en) 2018-11-15
ES2915266T3 (es) 2022-06-21
AU2016348524A1 (en) 2018-05-17
CO2018004800A2 (es) 2018-10-31
CL2018001217A1 (es) 2018-08-03
AU2016348524B2 (en) 2021-01-28
MY194461A (en) 2022-11-30
IL258862B (en) 2021-02-28
JP2021050243A (ja) 2021-04-01
TN2018000130A1 (en) 2019-10-04
HK1253029A1 (zh) 2019-06-06
JP2018531981A (ja) 2018-11-01
PE20181010A1 (es) 2018-06-26
EP3371164B1 (en) 2022-03-16
WO2017079641A1 (en) 2017-05-11
SA518391518B1 (ar) 2021-06-13

Similar Documents

Publication Publication Date Title
MX2018005215A (es) Derivados de n-[2-(1-bencilpiperidin-4-il)etil]-4-(pirazin-2-il)-p iperazin-1-carboxamida y compuestos relacionados como antagonistas del receptor muscarinico 4 (m4) para el tratamiento de enfermedades neurologicas.
PH12019500004A1 (en) 5,7-dihydro-pyrrolo-pyridine derivatives for treating neurological and neurodegenerative diseases
PH12020550631A1 (en) New catecholamine prodrugs for use in the treatment of parkinson`s disease
CY1117622T1 (el) Πυριμιδινες αναστολεις toy pde10
HK1217486A1 (zh) 作爲β-分泌酶抑制剂的全氟化环丙基稠合的1，3-恶嗪-2-胺化合物以及其使用方法
GEP20207149B (en) Allosteric modulators of nicotinic acetylcholine receptors
MX2020013099A (es) Compuestos heteroaromaticos y su uso como ligandos d1 de dopamina.
SA519401322B1 (ar) مركبات أريل كربوكساميد غير متجانسة كمثطبات لكيناز بروتين سيرين/ ثريونين متداخل مع المستقبل 2
BR112017019685A2 (pt) composto, composição farmacêutica, uso de um composto ou um sal ou um solvato farmaceuticamente aceitável do mesmo, e, método para tratamento de uma doença ou condição
CY1118021T1 (el) Παραγωγο αζολιου
CY1124574T1 (el) Προφαρμακο παραγωγου αμινοξεος
TW201613890A (en) Pyridine derivatives as muscarinic M1 receptor positive allosteric modulators
PH12016501864A1 (en) Chromene and 1, 1a, 2, 7b-tetrahydrocyclopropa[c]chromene pyridopyrazinediones as gamma-secretase modulators
JO3569B1 (ar) مركبات بروبيل حلقي متحد مع ثيازين-2-أمين كمثبطات انزيم بيتا سكريتاز وطرق استخدامها
WO2012044561A3 (en) 2-alkoxy pyrimidine pde10 inhibitors
TN2016000447A1 (en) Heteroaromatic compounds and their use as dopamine d1 ligands.
WO2012054366A3 (en) Substituted amino-triazolyl pde10 inhibitors
IN2014DN09826A (es)
WO2014150114A8 (en) Substituted pyridizinone derivatives as pde10 inhibitors
EA201990188A1 (ru) Производные 5,7-дигидропирролопиридина
EA201891038A1 (ru) Антагонисты мускаринового рецептора 4 и способы их применения